Can-Fite BioPharma announced that positive Phase 2a study results of Namodenoson, a drug for advanced pancreatic ductal adenocarcinoma, have been accepted for presentation at the ESMO Congress 2026. The study showed durable disease stabilization and encouraging survival in patients who had progressed after standard therapies, with one second-line patient alive over 18 months. Namodenoson, targeting the A3 adenosine receptor, has a strong safety profile and is being further developed in combination with chemotherapy in a planned Phase 2b trial. This recognition at a leading oncology conference supports continued development of Namodenoson for this hard-to-treat cancer.
Roku President Charles Collier sold 20,538 shares of the company, raising $3 million from the transaction. This insider sale could indicate personal financial planning or a shift in confidence, but no further details were provided. Investors may watc...
Bitcoin's blockchain split at block 961632, with the BIP-110-supporting Roughnecks mining two blocks on a minority chain now 18 blocks behind the main chain, which has reached block 961651. The mining difficulty remains high at 127.48 trillion, makin...
Tron's stablecoin supply reached approximately $91.8 billion in early August, increasing by $2 billion in the past month. Nearly 98% of this supply is Tether's USDT, making Tron the largest blockchain for USDT circulation since 2021. The network proc...
Roku President Charles Collier sold 20,538 shares of the company, generating $3 million in proceeds. This insider sale could indicate personal financial planning or a shift in confidence, which investors might watch closely. The transaction highlight...
SharpLink CEO Joseph Chalom warned that Ethereum's proposed EIP-8363, which would burn a portion of validator rewards as staking increases, might harm DeFi liquidity, raise borrowing costs, and discourage institutional ETH ownership. The proposal aim...
